drugset / Trial / NCT06024239

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of ABBV-932 in Healthy Adult Participants, Participants With Generalized Anxiety Disorder (GAD) and Participants With Bipolar Disorder (BPD)

NCT06024239 ↗

Phase 1 Completed 72 enrolled AbbVie
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to assess the pharmacokinetics, safety, and tolerability following multiple ascending oral doses of ABBV-932 or placebo in healthy adult participants, participants with Generalized Anxiety Disorder (GAD), and participants with bipolar disorder (BPD).

Timeline

Start
2023-08-31
Primary completion
2025-03-04
Completion
2025-03-04

Drugs

EvaluationDrugModalityDoseRoute
Subject ABBV-932 Unknown — Oral